Search

Author/Creator Chen, Yitian

11. Jujuboside B Reverse CUMS-Promoted Tumor Progression via Blocking PI3K/Akt and MAPK/ERK and Dephosphorylating CREB Signaling. (8th October 2022)

Authors:
Yang, Zhen; Cai, Weijia; Chen, Yitian; Guo, Zhijun; Xiao, Zhijun; Zhou, Ting; Cheng, Yuanchi; Xu, Feng
Other Names:
Meng Lingzhang Academic Editor.
Journal:
Journal of immunology research
Issue:
Volume 2022(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial. (August 2022)

Authors:
Yang, Ciqiu; Zhang, Junsheng; Zhang, Yi; Ji, Fei; Chen, Yitian; Zhu, Teng; Zhang, Liulu; Gao, Hongfei; Yang, Mei; Li, Jieqing; Cheng, Minyi; Wang, Kun
Journal:
Therapeutic advances in medical oncology
Issue:
Volume 14(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

18. USP12 positively regulates M‐MDSC function to inhibit antitumour immunity through deubiquitinating and stabilizing p65. Issue 4 (8th August 2022)

Authors:
Zhan, Xiaoxia; He, Qiuying; Sheng, Junli; Jiang, Xiaobing; Lin, Letao; Huang, Yulan; He, Shitong; Chen, Yitian; Li, Laisheng; Zeng, Zhijie; Hu, Shengfeng; Wang, Peng; Zhang, Yanling
Journal:
Immunology
Issue:
Volume 167:Issue 4(2022)
Page Start:
544
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗